Dr. Michael A. Friedman is President and Chief Executive Officer of City of Hope, a cancer research and treatment institution dedicated to innovation in basic and clinical biomedical research and delivery of exceptional patient care. Before this he was a senior vice president of research and development at Pharmacia Corporation. Following the events of September 11, 2001, he simultaneously served as chief medical officer for biomedical preparedness at the Pharmaceutical Research and Manufacturers of America. Dr. Friedman previously served as the U.S. Food and Drug Administration (FDA) Deputy Commissioner and was then tapped by the Clinton administration to serve as acting commissioner of the FDA. He helped to streamline the FDA’s review and approval process and protect the nation’s food and drug supply.
In 1983, Dr. Friedman joined the Division of Cancer Treatment at the National Cancer Institute, and went on to become the associate director of the Cancer Therapy Evaluation Program. Before joining the NCI, he spent nearly a decade at the University of California at San Francisco, as an associate professor of medicine directing the Cancer Research Institute. He joined the U.S. Public Health Service in 1970, ultimately attaining the rank of Rear Admiral and has served as an active duty and now reserve officer. He has received a number of commendations, including the Surgeon General’s Medallion, the FDA Commissioner’s Special Citation and the PHS Distinguished Service Medal.
Dr. Friedman received his Bachelor of Arts degree, magna cum laude, from Tulane University and a Doctorate in Medicine from the University of Texas. He completed postdoctoral training at Stanford University and the National Cancer Institute, and is board certified in Internal Medicine and Medical Oncology.
Tulane University, New Orleans, LA 70118 504-865-5000 email@example.com